SN
CRSP icon

Sittner & Nelson’s CRISPR Therapeutics CRSP Stock Holding History

Sittner & Nelson’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$240K Sell
5,051
-140
-3% -$7.38K 0.09% 151
2025
Q4 		$253K Buy
5,191
+140
+3% +$8.38K 0.09% 145
2025
Q3 		$327K Buy
5,051
+81
+2% +$4.65K 0.12% 113
2025
Q2 		$242K Buy
4,970
+580
+13% +$22.4K 0.1% 127
2025
Q1 		$149K Hold
4,390
– – 0.06% 160
2024
Q4 		$173K Buy
4,390
+653
+17% +$30.8K 0.07% 141
2024
Q3 		$176K Buy
3,737
+190
+5% +$9.64K 0.08% 139
2024
Q2 		$192K Sell
3,547
-300
-8% -$17.4K 0.09% 118
2024
Q1 		$262K Buy
3,847
+250
+7% +$17.9K 0.13% 100
2023
Q4 		$225K Sell
3,597
-90
-2% -$4.97K 0.12% 104
2023
Q3 		$167K Buy
3,687
+150
+4% +$7.75K 0.1% 117
2023
Q2 		$199K Hold
3,537
– – 0.11% 107
2023
Q1 		$160K Buy
3,537
+130
+4% +$6.31K 0.09% 130
2022
Q4 		$138K Sell
3,407
-20
-0.6% -$1.06K 0.08% 140
2022
Q3 		$224K Hold
3,427
– – 0.15% 103
2022
Q2 		$208K Hold
3,427
– – 0.14% 101
2022
Q1 		$215K Buy
3,427
+700
+26% +$44K 0.12% 99
2021
Q4 		$207K Buy
2,727
+210
+8% +$18.3K 0.12% 99
2021
Q3 		$282K Buy
2,517
+887
+54% +$111K 0.18% 80
2021
Q2 		$264K Buy
1,630
+430
+36% +$52.3K 0.19% 76
2021
Q1 		$146K Buy
+1,200
New +$181K 0.11% 105

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sittner & Nelson's CRSP Position: Q1 2026 in Review

Sittner & Nelson reduced its CRISPR Therapeutics (CRSP) stake by 2.7% in Q1 2026, selling an estimated $7.38K and leaving 5,051 shares worth $240K. The position accounts for 0.09% of the portfolio, ranked #151.

Sittner & Nelson first reported a position in CRSP in Q1 2021 and has held it in 21 quarters since. The position peaked at $327K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Sittner & Nelson held 5,051 shares of CRISPR Therapeutics worth $240K as of Q1 2026.
  • Sittner & Nelson sold 140 CRISPR Therapeutics shares in Q1 2026, an estimated $7.38K.
  • CRISPR Therapeutics made up 0.09% of Sittner & Nelson's portfolio in Q1 2026, its #151 holding.
  • Sittner & Nelson first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Sittner & Nelson's CRISPR Therapeutics position peaked at $327K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Sittner & Nelson's 13F filing for Q1 2026, filed 12 May 2026.